Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Allogene Therapeutics Terminates Asian CAR-T Joint Venture with Overland Pharmaceuticals – Strategic Retreat from Allogeneic Cell Therapy Market in Asia

Fineline Cube May 18, 2026
Company Deals

Eli Lilly Commits $50M to UNICEF USA Alliance Targeting Non-Communicable Disease Prevention in Children Across 21 LMICs

Fineline Cube May 15, 2026
Company Deals

TenNor Therapeutics Raises $71M in Hong Kong IPO – Antimicrobial Pipeline Targets H. pylori and Implant-Associated Infections

Fineline Cube May 14, 2026
Company Deals Drug

Fosun Pharma Secures Global Rights to AriBio’s Alzheimer’s Drug AR1001 in $240M Deal – PDE-5 Inhibitor Shows Promise in Phase III

Fineline Cube May 14, 2026
Company Deals

Merck & Co. Forges Four Strategic Partnerships with Chinese Biotechs to Advance Autoimmune and Oncology Pipeline Through MCICC Platform

Fineline Cube May 14, 2026
Policy / Regulatory

China Issues National Guidelines for Home Hospital Bed Services to Address Healthcare Access for Vulnerable Populations

Fineline Cube May 15, 2026
Company Drug

Harbour BioMed Unveils Preclinical Data for LET003 – AI-Discovered ACVR2A/2B Antibody Shows Best-in-Class Potential in Obesity Combination Therapy with GLP-1 Drugs

Fineline Cube May 18, 2026
Company Drug

AstraZeneca and Daiichi Sankyo’s ENHERTU Secures Dual FDA Approval for HER2-Positive Early Breast Cancer – Neoadjuvant and Adjuvant Indications Supported by Landmark Phase 3 Data

Fineline Cube May 18, 2026
Company Deals

JancsiTech Raises Tens of Millions in Angel Round Led by Yuanbio Venture Capital

Fineline Cube Nov 30, 2022

JancsiTech, a precision nuclear medicine specialist based in Shenzhen, has reportedly raised “tens of millions”...

Company Drug

FDA Rejects Spectrum’s Poziotinib NDA for NSCLC Treatment

Fineline Cube Nov 30, 2022

US-based Spectrum Pharmaceuticals Inc. (Nasdaq: SPPI) announced last week that its New Drug Application (NDA)...

Company

Sino Biological to Invest RMB 1 Billion in Beijing Bio-Pharmaceutical Park

Fineline Cube Nov 30, 2022

Sino Biological, Inc. (SHE: 301047) has announced plans to invest RMB 1 billion (USD 140...

Company Drug

Luye Pharma Launches Toludesvenlafaxine in China for Depression Treatment

Fineline Cube Nov 29, 2022

China-based Luye Pharma Group (HKG: 2186) has officially launched its Category 1 chemical drug toludesvenlafaxine...

R&D

Hong Kong Researchers Identify New Target for Epilepsy Treatment

Fineline Cube Nov 29, 2022

Researchers at the University of Hong Kong have published the results of a study that...

Company Drug

Hope Medicine Gains Global Approval for Phase II Trial of HMI-115

Fineline Cube Nov 29, 2022

China-based Hope Medicine Inc. has announced receiving approval to conduct a global multi-center Phase II...

Company Deals

Full-Life Technologies Acquires Focus-X Therapeutics to Expand Pipeline

Fineline Cube Nov 29, 2022

Shanghai-headquartered Full-Life Technologies Ltd has announced the acquisition of New Jersey-based Focus-X Therapeutics. The move...

Policy / Regulatory

NMPA Launches Electronic Certificates for API and Pharmaceutical Product Exports

Fineline Cube Nov 29, 2022

The National Medical Products Administration (NMPA) has released a notification regarding the initiation of two...

Company Deals

I-Mab Partners with Wuxi Diagnostics to Advance Biomarker-Driven Clinical Studies

Fineline Cube Nov 29, 2022

China-based I-Mab (NASDAQ: IMAB) has announced a strategic partnership with compatriot firm Wuxi Diagnostics to...

Company Deals

Trinomab Biotech Raises RMB 750 Million in Pre-IPO Financing Round

Fineline Cube Nov 29, 2022

China-based Trinomab Biotech Co., Ltd reportedly raised RMB 750 million (USD 104.5 million) in a...

Company

Alibaba Health Reports 22.9% Revenue Growth in H1 2022

Fineline Cube Nov 29, 2022

China-based Alibaba Health Information Technology Ltd (HKG: 0241) has released its financial report for the...

Company Deals

3D Medicines Set for IPO in Hong Kong, Aiming to Raise Up to USD 55 Million

Fineline Cube Nov 29, 2022

China-based 3D Medicines Inc. (HKG: 1244) is set to make an initial public offering (IPO)...

Company Policy / Regulatory

China’s Medical Product Trade Surplus Declines Amid COVID-19 Impact

Fineline Cube Nov 28, 2022

The China Chamber of Commerce for Import and Export of Medicines and Health Products (CCCMHPIE)...

Company Deals

Nuance Pharma Partners with DKSH to Launch Bentrio Nasal Spray in Hong Kong and Macau

Fineline Cube Nov 28, 2022

China-based Nuance Pharma has announced a partnership with DKSH Hong Kong Business Unit Healthcare to...

Deals

Biocytogen and ADC Therapeutics Enter Evaluation and Option Agreement

Fineline Cube Nov 28, 2022

China-based Biocytogen Pharmaceuticals (Beijing) Co., Ltd has announced an evaluation and option agreement with Swiss...

Company Drug

Lyvgen Biopharma Initiates Phase II Study for LVGN7409 in Advanced NSCLC

Fineline Cube Nov 28, 2022

Shanghai-based immuno-oncology therapeutics specialist Lyvgen Biopharma has announced the initiation of an open-label, multi-center, randomized...

Company Deals

ZSHK Laboratories Raises RMB 100 Million in Series B Financing Round

Fineline Cube Nov 28, 2022

China-based pre-clinical Contract Research Organization (CRO) ZSHK Laboratories Limited has reportedly raised close to RMB...

Company

Ascentage Pharma Receives Drug Production License for Suzhou Plant

Fineline Cube Nov 28, 2022

Suzhou-based Ascentage Pharma (HKG: 6855) has announced receiving a Drug Production License (A license) following...

Company Drug

Everest Medicines’ Nefecon Gains Accelerated Approval in Taiwan and South Korea

Fineline Cube Nov 28, 2022

China-based Everest Medicines (HKG: 1952) has announced receiving Accelerated Approval Designation (AAD) from the Taiwan...

Company

Taizhou-Wuxi-Lianyungang Biomedicine Hub Launched at China Medical Expo

Fineline Cube Nov 28, 2022

The 13th China (Taizhou) International Medical Expo witnessed the launch of the Taizhou-Wuxi-Lianyungang national biomedicine...

Posts pagination

1 … 595 596 597 … 667

Recent updates

  • Harbour BioMed Unveils Preclinical Data for LET003 – AI-Discovered ACVR2A/2B Antibody Shows Best-in-Class Potential in Obesity Combination Therapy with GLP-1 Drugs
  • Allogene Therapeutics Terminates Asian CAR-T Joint Venture with Overland Pharmaceuticals – Strategic Retreat from Allogeneic Cell Therapy Market in Asia
  • AstraZeneca and Daiichi Sankyo’s ENHERTU Secures Dual FDA Approval for HER2-Positive Early Breast Cancer – Neoadjuvant and Adjuvant Indications Supported by Landmark Phase 3 Data
  • Roche’s Tecentriq Secures FDA Approval for ctDNA-Guided Adjuvant Treatment in Muscle-Invasive Bladder Cancer – First MRD-Directed Immunotherapy with 41% Mortality Reduction
  • Biogen’s Zorevunersen Receives China Breakthrough Therapy Designation for Dravet Syndrome – First ASO Targeting SCN1A Gene in Rare Epileptic Encephalopathy
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Harbour BioMed Unveils Preclinical Data for LET003 – AI-Discovered ACVR2A/2B Antibody Shows Best-in-Class Potential in Obesity Combination Therapy with GLP-1 Drugs

Company Deals

Allogene Therapeutics Terminates Asian CAR-T Joint Venture with Overland Pharmaceuticals – Strategic Retreat from Allogeneic Cell Therapy Market in Asia

Company Drug

AstraZeneca and Daiichi Sankyo’s ENHERTU Secures Dual FDA Approval for HER2-Positive Early Breast Cancer – Neoadjuvant and Adjuvant Indications Supported by Landmark Phase 3 Data

Company Drug

Roche’s Tecentriq Secures FDA Approval for ctDNA-Guided Adjuvant Treatment in Muscle-Invasive Bladder Cancer – First MRD-Directed Immunotherapy with 41% Mortality Reduction

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.